Join to view full profile
4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902
Dr. Cashen is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Amanda Cashen is a Professor of Medicine and the Associate Chief of Hematologic Malignancies at Washington University in St. Louis School of Medicine. She is based in Saint Louis, MO. Her education includes a medical degree from Washington University in St. Louis School of Medicine, as well as a residency and fellowship in hematology and medical oncology at the Washington University/B-JH/SLCH Consortium. Dr. Cashen is experienced in areas including lymphomas, leukemias, and stem cell transplantation and cellular therapies.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2006- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
- WashU MedicineClass of 1999
Certifications & Licensure
IL State Medical License 2020 - 2029
MO State Medical License 2000 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2013-2017
Clinical Trials
Publications & Presentations
PubMed
- Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.Felicia Gomez, Lauren Shea, Sivasankar Annamalai Sharavanan, David Russler-Germain, Matthew Mosior
Cancer Genetics. 2026-06-01 - 3 citationsNew comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop
Blood Advances. 2026-01-13 - Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report.Tung-Lin Chiang, John Frater, Amanda Cashen
Leukemia Research Reports. 2026-01-01
Journal Articles
- The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLLMatthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Abstracts/Posters
- Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplan...Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive LymphomasAmanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024- Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007December 5th, 2024
- World Leaders in Ending Blood CancerNovember 14th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
